Lamivudine

Generic Name: Lamivudine

Brand Names: Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁N_₃O_₃S

CAS Number: 134678-17-4

Unique Ingredient Identifier: 2T8Q726O95

Background: A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication: For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions: Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2003-01-01

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 775

Registration Number: NCT00050895

Locations: 🇺🇸
IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States

and more 57 locations

Once-Daily Drug Regimen for HIV-Infected Patients

Phase 1

Completed

Conditions: Acquired Immunodeficiency Syndrome
HIV Infections

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT00001968

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

Phase 3

Completed

Conditions: HIV Infection
Infection, Human Immunodeficiency Virus I

First Posted Date: 2002-09-23

Last Posted Date: 2020-03-24

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 240

Registration Number: NCT00046176

Locations: 🇵🇷
GSK Investigational Site, Rio Piedras, Puerto Rico

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus I
HIV Infection

First Posted Date: 2002-09-04

Last Posted Date: 2020-03-24

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 166

Registration Number: NCT00044577

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2002-05-30

Last Posted Date: 2006-07-27

Lead Sponsor: Abbott

Target Recruit Count: 40

Registration Number: NCT00038220

Locations: 🇺🇸
Aaron Diamond AIDS Research Center - Rockefeller University, New York, New York, United States

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Phase 2

Completed

Conditions: Hepatitis B, Chronic

First Posted Date: 2002-04-29

Last Posted Date: 2021-02-18

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 79

Registration Number: NCT00034359

Locations: Clinical Trial Site, Novi Sad, Former Yugoslavia

Study of Anti-HIV Therapy Intensification

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2002-04-23

Last Posted Date: 2012-05-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 22

Registration Number: NCT00034086

Locations: 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸
Case CRS, Cleveland, Ohio, United States
🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-12-21

Last Posted Date: 2011-03-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 250

Registration Number: NCT00028327

Locations: 🇺🇸
Beth Israel Med Ctr, New York, New York, United States
🇺🇸
Univ of California San Francisco, San Francisco, California, United States
🇺🇸
Washington Univ School of Medicine, St Louis, Missouri, United States

and more 6 locations

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-05-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 110

Registration Number: NCT00000923

Locations: 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States
🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸
Case CRS, Cleveland, Ohio, United States

and more 9 locations

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002245

Locations: 🇺🇸
LAC / USC Med Ctr / Infectious Diseases, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy